EyePoint Pharmaceuticals Business Summary

EyePoint Pharmaceuticals, Inc. (EYPT) is a clinical-stage biopharmaceutical company that has strategically pivoted from a specialty pharma model to a pure-play developer of sustained-release therapeutics for serious retinal diseases. The company’s core value proposition is built upon its proprietary Durasert E™ technology, a bioerodible miniaturized injectable insert designed to deliver small molecules over several months. Currently, EyePoint generates de minimis revenue following the 2023 divestiture of its YUTIQ® and DEXYCU® commercial assets, with its financial model now centered on the high-stakes clinical advancement of its lead candidate, DURAVYU™ (EYP-1901). As of March 2026, DURAVYU is in pivotal Phase 3 trials (LUGANO and LUCIA) for wet age-related macular degeneration (wet AMD), with topline data expected in mid-2026, and has recently initiated Phase 3 trials (COMO and CAPRI) for diabetic macular edema (DME). EyePoint operates in a highly competitive long-acting retinal therapy market, primarily contending with Kodiak Sciences, Ocular Therapeutix, and REGENXBIO, positioning itself as a potential first-to-market provider of a sustained-release tyrosine kinase inhibitor (TKI) to reduce the treatment burden of frequent intravitreal injections. Leadership is spearheaded by President and CEO Jay S. Duker, M.D., a renowned retinal specialist and former Director of the New England Eye Center, who transitioned from COO to CEO in July 2023 to lead the company’s clinical transformation. In February 2026, the team was further strengthened by the appointment of Michael Campbell as Chief Commercial Officer, a strategic hire with deep pedigree from Genentech where he led the landmark launch of Lucentis®. The executive suite also includes EVP and CFO George O. Elston, who manages the company’s capital strategy and a cash runway extending into 2027. The Board of Directors is chaired by Dr. Göran Ando, former Chairman of Novo Nordisk, and includes Vice-Chair Nancy Lurker, the company’s former CEO. EyePoint maintains a strong institutional investor base, featuring prominent healthcare-focused funds such as RA Capital Management, Federated Hermes, and TCG Crossover, reflecting significant market confidence in the Durasert E™ platform’s late-stage clinical potential.